Lv33
350 积分 2022-05-26 加入
IDF Diabetes Atlas 11th edition 2025: global prevalence and projections for 2050
49分钟前
已完结
Ulcerative colitis: clinical biomarkers, therapeutic targets, and emerging treatments
5天前
已完结
ABX464 (obefazimod) for moderate-to-severe, active ulcerative colitis: a phase 2b, double-blind, randomised, placebo-controlled induction trial and 48 week, open-label extension
14天前
已完结
皖公网安备34019202002308
